Zhejiang Gaorong Cosmetic Co., Ltd. Added to Import Alert 66-40:…

Regulatory Event

On July 31, 2026, the Food and Drug Administration (FDA) added Zhejiang Gaorong Cosmetic Co., Ltd. to Import Alert 66-40, the agency’s Detention Without Physical Examination (DWPE) list for firms that have not met drug current Good Manufacturing Practice (CGMP) requirements. The listing covers the firm’s facility at No. 88 Xixi Street, Linjiang Industrial Park, Jinhua, Zhejiang, China, and it entered the Red List as a brand-new firm addition, with all fourteen product-line rows dated the same day. That is a materially broader entry than most single-firm IA 66-40 additions: it spans vitamins/minerals and dietary-supplement-as-drug categories across non-prescription, prescription, and investigational status (product codes 54-D through 54-I); pharmaceutical necessities and containers for drug and biologic use (code 55); Human and Animal Therapeutic Biologic and Biosimilar Drugs (code 58); and all seven sequential general human and animal drug codes, 60 through 66, without a single gap in the sequence. Every product line covered by the listing is now subject to automatic detention at the US port of entry; release requires the importer to demonstrate CGMP conformance to the Center for Drug Evaluation and Research (CDER) before any shipment clears.

One detail is worth stating plainly because it is directly on the Red List entry itself, not an inference: the firm’s registered corporate name is “Zhejiang Gaorong Cosmetic Co., Ltd.” — on its face, a cosmetics manufacturer. Yet the DWPE scope FDA applied reaches well beyond cosmetics into dietary-supplement-as-drug product lines, pharmaceutical necessities, therapeutic biologic and biosimilar drug codes, and the full general human and animal drug code range. This is not a claim about what caused the listing; FDA has not published a distinct deficiency narrative for this firm, and the Red List entry cites only the standard “not operating in conformity with CGMP requirements” language uniformly across all fourteen rows. What the entry does establish, factually, is that this facility is registered to manufacture across drug, biologic, and dietary-supplement CGMP-covered categories despite a corporate name that identifies it only as a cosmetics company — a mismatch between trade identity and registered manufacturing scope that matters directly for supplier qualification, addressed below. No Form 483, inspection classification, or companion Warning Letter for Zhejiang Gaorong Cosmetic Co., Ltd. was located in FDA’s public Warning Letter database or in general web search as of this writing, and no company statement or press coverage was located either.

What the Record Documents

DWPE is not a warning; it is an operational barrier. Under Section 801 of the Federal Food, Drug, and Cosmetic Act and 21 CFR § 1.94, FDA may detain a shipment without physical examination once the exporting firm appears on the IA 66-40 Red List, and the burden falls to the owner, consignee, or other responsible party to provide documentation showing the CGMP violation has been adequately corrected before release will be considered. In practice, every US customer sourcing dietary-supplement-as-drug products, pharmaceutical necessities, biologic or biosimilar material, or any general drug product from this facility now faces halted supply unless the importer of record initiates a Compliance Monitoring Program (CMP): a validated sampling plan, testing through an FDA-qualified laboratory, and batch-by-batch release submissions to the responsible FDA district office, sustained until FDA is willing to schedule a reinspection.

Prior IA 66-40 cases involving facility-wide, multi-category listings offer a useful reference point for scale and timeline, even though the specific deficiency category here has not been publicly confirmed. Wockhardt’s Waluj facility was listed in 2013 following an FDA inspection documenting data manipulation under 21 CFR §§ 211.68(b) and 211.194(a); the resulting CMP covered the site’s entire finished product line, and Wockhardt’s US revenue declined an estimated $130 million in the following year as customers qualified alternative suppliers. Sun Pharmaceutical’s Halol facility, listed in December 2014 after a Warning Letter citing data integrity and sterility assurance failures, disrupted supply of roughly 150 products before completing an 18-month CMP and two consecutive satisfactory reinspections en route to removal in March 2017. Ranbaxy’s Paonta Sahib facility, listed for data integrity failures under § 211.194(a), required more than four years of batch-by-batch CMP testing before reinspection. Those cases involved large-volume generic drug manufacturers with a known pharmaceutical identity; Zhejiang Gaorong’s listing is broader in raw product-code count than any of the recent additions tracked in this series, yet the firm presents publicly as a cosmetics company with no independently verifiable pharmaceutical manufacturing profile. What the precedents establish as a general mechanism, regardless of a firm’s apparent core business, is that DWPE does not lift until a firm demonstrates — through sustained CMP performance and a satisfactory reinspection — that the underlying quality system, not just the language on the Red List, has been corrected.

Technical and Quality Context

For Zhejiang Gaorong, a credible remediation pathway starts with transparency: engaging the FDA district office responsible for the listing, obtaining the underlying inspection findings if a Form 483 or equivalent record exists, and building a Corrective and Preventive Action (CAPA) program scoped to whatever CGMP gap FDA actually identified, rather than to the general language on the Red List. Given the blanket nature of the listing across fourteen product codes touching drug, biologic, and dietary-supplement manufacturing, a credible corrective action plan will likely need to address quality system fundamentals across the full registered operation rather than a single product line: written production and process control procedures under 21 CFR § 211.100(a), laboratory controls and specifications under § 211.160(a)(b), production and process control review before batch release under § 211.192, and laboratory record integrity under § 211.194(a) are among the areas that general CGMP non-conformance findings most commonly touch for multi-category manufacturers, based on the pattern reflected in prior IA 66-40 actions, though the specific deficiency here has not been publicly confirmed.

US companies that source dietary supplements marketed as drugs, pharmaceutical necessities, biologic or biosimilar material, or any general drug product from Zhejiang Gaorong should treat this listing as an immediate supplier qualification trigger — and should specifically check whether their own supplier list would have caught this facility at all. A cosmetics-branded corporate name is not a reliable filter for CGMP exposure: this facility’s registered manufacturing scope, as reflected on the Red List itself, extends well past what its name implies. That means auditing current inventory and supply agreements against this facility by legal entity name and address rather than by assumed product category, confirming with any distributor or repackager whether Zhejiang Gaorong material sits further upstream in a supply chain, and beginning an alternative-sourcing assessment in parallel with monitoring FDA’s Warning Letter postings for any underlying finding that may still surface.

Decision Relevance

XGene Consulting supports companies at both ends of this exposure: importers and brand owners assessing whether a listed supplier’s CGMP gaps create downstream liability — including gaps hidden by a supplier’s non-pharmaceutical trade identity — and manufacturers like Zhejiang Gaorong building the CMP documentation package, root cause assessment, and reinspection readiness plan FDA expects before considering removal from Import Alert 66-40. If you manage a supplier relationship tied to a site on Import Alert 66-40, or you are the site working to get off it, connect with me on LinkedIn or through xgeneconsulting.com — the earlier a disciplined CMP strategy starts, the shorter the DWPE period tends to run.